Newcourt Acquisition Corp
NCACW
NASDAQ Global Market0.05
USD
+0.01
- -
CIK
0001849475
ISIN
KYG6448C1298
CUSIP
G6448C129
Return %
Stock
S&P500
1Y
13.75
26.53
3Y
-90.90
76.60
5Y
-90.90
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Marc Gregory Balkin
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 2201 Broadway Oakland CA United States of America 94612
- CIK
- 0001849475
- Similar Companies
- Business
- Newcourt Acquisition Corp is a special purpose acquisition company (SPAC) originally incorporated in 2021 and headquartered in Oakland, California. The company focuses on identifying and merging with high-potential enterprises, facilitating strategic mergers that generate shareholder value. Newcourt Acquisition Corp does not have significant standalone operations; instead, it serves as a vehicle for business combinations. Recently, it completed a business combination transaction with Psyence Therapeutics Corp, a company specializing in psychedelic medicine with operations including licensed commercial psilocybin mushroom cultivation and clinical development for palliative care. This reverse merger, finalized in early 2024, makes Psyence Therapeutics a wholly owned subsidiary of Newcourt Acquisition Corp. Psyence operates internationally with presence in Southern Africa, the United States, and the United Kingdom, focusing on natural psilocybin production, therapeutics, and research collaboration. This transaction marked a significant strategic shift for Newcourt, transforming from a SPAC to an operating entity within the psychedelics healthcare sector. The company continues to trade on the Nasdaq under the ticker NCAC. This transaction reflects Newcourt Acquisition Corp's latest major change, pivoting to an active commercial and clinical stage business in the biotechnology and psychedelic medicine industry.